Page 17 - Martin Shkreli Case Study

However, events were beginning to move against Shkreli

"As early as next week, the Board should remove Martin as CEO. ... the
price drop has to be significant and tied to something. ... This cannot be
seen as something that appears to be as arbitrary as the price hike in
the first place." — Outside PR consultant, Oct. 8. (4)

Moreover, earlier in the month, New York Attorney General Eric
Schneiderman's antitrust bureau said it was investigating Turing
Pharamaceuticals over concerns that the company might be 'unlawfully'
restraining competition.

It was thought that Turing was reportedly doing this by distributing
Daraprim through a limited number of specialty pharmacies in order to
prevent generic manufacturers from obtaining access to samples to
make their own version.